Cytokinetics (CYTK) Prices 7.29M Share Common Offering at $24/Sh

Pre-Open Movers 07/16: (LCI) (DELL) (AA) Higher; (TCDA) (NCLH) (GENE) Lower (more...)

Pre-Open Stock Movers

Nabriva Therapeutics plc (NASDAQ: NBRV) 57.9% HIGHER; announced that it has entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO® (tedizolid phosphate) in the United States and certain of its territories. SIVEXTRO is an oxazolidinone-class antibacterial indicated in adults and pediatric patients 12 years of age and older for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by certain susceptible Gram-positive microorganisms.

AC Immune SA (NASDAQ:... More

After-Hours Stock Movers 07/15: (RTIX) (DELL) (AA) Higher; (TCDA) (CYTK) (TWTR) Lower (more...)

After-Hours Stock Movers

Tricida, Inc. (Nasdaq: TCDA) 35% LOWER; announced today that on July 14, 2020, the Company received a notification from the U.S. Food and Drug Administration (FDA) stating that, as part of its ongoing review of the Companys New Drug Application (NDA), the FDA has identified deficiencies that preclude discussion of labeling and postmarketing requirements/commitments at this time. The FDA stated that the notification does not reflect a final decision on the information under review.

RTI Surgical Holdings, Inc. (Nasdaq: RTIX)... More

Cytokinetics (CYTK) Announces Proposed $150M Share Common Offering

Cytokinetics, Incorporated (NASDAQ: CYTK) today announced plans to offer, subject to market and other conditions, $150,000,000 of shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or... More

Cytokinetics (CYTK) PT Raised to $29 at JMP Securities

JMP Securities raised its price target on Cytokinetics (NASDAQ: CYTK) to $29.00 (from $23.00) while maintaining a Market Outperform rating.... More